

Guojia WU

(+86) 18058740766 | wuguoja@tmu.edu.cn | github.com/wunaiwuhuang

RESEARCH INTEREST

With a strong foundation in both basic medicine and bioinformatics, I specialize in applying bioinformatics techniques to investigate cancer biology, particularly focusing on the roles of genomics and epigenetic modifications in tumor development and progression. I am also interested in tumor immune infiltration and its interaction with the genomic and epigenetic landscape. I am passionate about identifying potential therapeutic targets through integrative bioinformatics analyses, and exploring how genetic and methylation alterations contribute to cancer development and treatment response.

EDUCATION



• Tianjin Medical University

Sep. 2021 - Jun. 2026 (Expected)

Bachelor of Science in Basic Medicine

Tianjin, China

◦ **GPA:** 3.77/4.00; **RANKING** : 1st out of 22 students; **IELTs:** 7.0, C 1;

RESEARCH PROJECTS

• Pan-Cancer Atlas of TCGA ipaQTM (Independent project)

Mar. 2025 - Present

Supervisor: Prof. Yang Yang Supported by YY Lab, TMU;



- **Investigated the relationship between DNA methylation and intronic pre-mRNA polyadenylation (IPA) across 23 cancer types using TCGA data, and further explored the underlying mechanisms**, including trans effects from genes such as *CDK12*, *BCL2*, and *CPSF1*, as well as cis effects involving DNA structure and transcription factor binding (e.g., *CTCF*). These findings suggested a novel regulatory layer in cancer transcriptomics.
- Constructed a pan-cancer ipaQTM (intron polyadenylation quantitative trait methylation) map using In-pact and MatrixEQTL, **identifying over 500,000 cis-/trans- associations, Discovered thousands of putative IPA regulators.**

• Glycolysis-Related Subtypes in Hepatocellular Carcinoma (Independent project)

Mar. 2025 - Present

Supervisor: Prof. Yongmei Li Supported by TMU Yongmei Li Lab;



- Identified key glycolysis-related genes (e.g., *SMG1*, *SRRM2*, *STAG1*) associated with hepatocellular carcinoma (HCC) progression through integrative analysis of RNA-seq, somatic mutation, and DNA methylation data. **Constructed a glycolytic gene signature using PCA and CatBoost-based feature selection from 30 candidate genes, and developed a molecular subtyping model based on non-negative matrix factorization (NMF).** This model stratified patients into clinically distinct subtypes with significant differences in survival, tumor stage, and metabolic activity, thereby demonstrating potential diagnostic and prognostic utility.
- Glycolysis levels inferred from RNA-seq were correlated with immune infiltration patterns by integrating ESTIMATE and CIBERSORT algorithms, revealing subtype-specific immune microenvironments relevant to immunotherapy response.

• Comprehensive Benchmark of DNN-Based pMHC Predictors (Independent project)

Sep. 2024 - Jan. 2025

Supervisor: Prof. Yang Yang Supported by TMU YY Lab;



- Benchmarked 17 state-of-the-art DNN-based tools for HLA-I peptide binding prediction using a **self-curated dataset of 290,000+ peptides across 44 alleles. Assessed model accuracy, robustness, and interpretability; incorporated SHAP and LIME to reveal internal mechanisms and feature contributions.**
- Found self-attention models (STMHCpan, BigMHC) achieved best overall performance, while capsule-based CapsNet-MHC_AN showed strong generalizability. Demonstrated that models trained on eluted ligand data outperform those using binding affinity data; ensemble strategies further improved reliability.
- Provided actionable guidelines for model selection, data integration, and the design of interpretable, clinically useful immunoinformatics tools.



• The role of HADH Isoform 3 in Endometrial Cancer (Independent project)

Mar. 2023 - Aug. 2024


Supervisor: Prof. Yongmei Li Supported by TMUUIROP Fund (1,000 RMB);



- **Identified the link between the fatty acid metabolism gene HADH and endometrial cancer (EC) using RNA-seq, genomics, and metabolomics data analysis.** Discovered *HADH* isoform 3 is downregulated in EC through *DDX3X* suppression, leading to activation of the *MEK-ERK* signaling pathway and promotion of malignant EC phenotypes.

- Demonstrated the therapeutic potential of *HADH* as a biomarker for EC, and its role in tumor infiltration and microenvironment construction.
- Provided insights for improved EC diagnosis, treatment, and prognosis monitoring by mapping the complete pathway of *HADH-DDX3X-MEK/ERK* interaction.
- **The role of Raptor in Post-Ischemic Angiogenesis (Collaborative project)** Apr. 2022 - Aug. 2023
Supervisor: Prof. Ding Ai *Supported by TMUUIROP Fund (20,000 RMB);* 
- Investigated the role of Raptor, a core component of the mTORC1 complex, in post-ischemic angiogenesis using both in vivo and in vitro models.
- Explored the contribution of mTORC1 signaling in vascular regeneration, providing novel insights into the molecular regulation of ischemia-induced angiogenesis. Potentially offering new therapeutic strategies for peripheral artery disease by targeting the Raptor/mTORC1 pathway to enhance revascularization and tissue recovery.
- **The role of Annexin A2 in Hepatocarcinogenesis (Collaborative project)** Apr. 2022 - Aug. 2023
Supervisor: Prof. Chunjiang Wang *Supported by TMUUIROP Fund (10,000 RMB);* 
- Investigated the differential roles of *ANXA2* in normal liver regeneration and hepatocellular carcinoma (HCC) development. Identified *ANXA2* upregulates cholesterol biosynthesis, enhancing hepatocyte proliferation via increased intracellular cholesterol.
- Combined transcriptomic and metabolomic approaches to explore how *ANXA2*-mediated cholesterol regulation contributes to HCC progression. Found *ANXA2* as a potential dual-function target to simultaneously suppress HCC and promote normal liver regeneration after partial hepatectomy.

PUBLICATIONS




A=RESEARCH ARTICLE, R=REVIEW, P=PUBLICATION, S=IN SUBMISSION 

- [AS.1] Wu, G., Liu, X., Wang, Y., & Yang, Y. (2025). Comprehensive evaluation and interpretative insights of peptide-HLA binding prediction tools using explainable artificial intelligence. *bioRxiv*.
- [AP.1] Sun, L., Zhai, S., Wu, G., Gu, J., Huang, Y., Hong, D., Wang, J., & Li, Y. (2024). Diagnostic sensitivity of immune-inflammatory cell proportion in early diagnosis of endometrial cancer. *Clinical Surgical Oncology*.
- [AS.2] Li, W., Guo, R., Zhang, R., Wu, G., Chen, R., & Wang, D. (2025). A bibliometric analysis of immunotherapy in glioblastoma. Manuscript under review.
- [RP.1] Wu, G., Zhai, S., Sun, X., Huang, Y., Li, Y., & Sun, L. (2024). progress of the effect of hydroxyacyl-coenzyme A dehydrogenase in cancer development and its mechanism. *Basic & Clinical Medicine*.

ACADEMIC SKILLS

- **Programming Languages:** R, Python, html and Shell.
- **Wet Lab Techniques:** Western blotting, DNA electrophoresis, plasmid construction and extraction, PCR, cell culture, migration and invasion assays, CCK-8 assay, tumor formation in mice, immunohistochemistry, etc.
- **Bioinformatics Skills:** RNA-seq analysis, database construction, sequence alignment, methylation and mutation analysis, CNV detection, gene enrichment and survival analysis, tumor subtyping, PPI network analysis, immune cell infiltration, Seurat-based single-cell analysis, QTL mapping, XAI techniques (SHAP, LIME) etc.
- **Research Skills:** Operating system proficiency (Windows, CentOS, Mint, Ubuntu); Presentation (LaTeX, PowerPoint, Photoshop, Adobe Illustrator); Academic writing; Data processing; Reference management, etc.

HONOUR AND SCHOLARSHIP

- **TianJin Medical University Scholarship – Merit Student** 2021 - 2022
TianJin Medical University 
- Ranked in top 1% of students in TianJin Medical University.
- **TianJin Medical University Scholarship – First Prize** 2022 - 2023
TianJin Medical University 
- Ranked in top 5% of students in TianJin Medical University.
- **TianJin Medical University Scholarship – First Prize** 2023 - 2024
TianJin Medical University 
- Ranked in top 5% of students in TianJin Medical University.

EXPERIENCES AND AWARDS

- **Teaching Assistant in Pathogenic Organisms** Apr. 2023- Jun. 2023
Tianjin Medical University, College of Basic Medicine in association with Prof. Yongmei Li
- **Executive Member, Basic Medicine Student Association** Sep. 2021 - Jun. 2025
College of Basic Medicine, Tianjin Medical University [🌐]
 - Executed a wide range of volunteer programs within the College of Life Sciences, including social practice, community outreach, and campus-wide events such as the university sports meeting and services for the visually impaired.
 - Led the recruitment and training of new volunteers, and designed engaging volunteer initiatives to enhance student union participation in public service.
- **Third Prize, International Forum on Basic Medical Sciences** Aug. 2024
National Demonstration Center for Experimental Education [🌐]
 - Led Tianjin Medical University's first participation in the Belt and Road International Track; responsible for experimental design, and delivered the entire presentation and defense in English as team leader.
- **Third Prize in the Chinese Mathematics Competitions** Dec. 2023
Chinese Mathematical Society [🌐]
- **Third prize, TianJin Chemistry competition** Oct. 2023
Tianjin Municipal Education Commission [🌐]
- **Third prize, TianJin biology experimental competition** Oct. 2024
Tianjin Municipal Education Commission [🌐]
- **First Prize (best), Internet Innovation and Entrepreneurship Competition** 2022 - 2024
Ministry of Education of the People's Republic of China [🌐]
 - Participated in the entrepreneurship track of the Internet Innovation and Entrepreneurship Competition for three consecutive years, serving as project leader or core member. Got over 8 awards in this competitions.
- **Second Prize (best), Challenge Cup National undergraduate entrepreneurship plan competition** 2023 - 2024
Ministry of Education of the People's Republic of China [🌐]
 - Participated in the Challenge Cup innovation track for two consecutive years as project leader, successfully leading the proposal submission and project execution each year. Got over 3 awards in this competitions.
- **Second Prize (best), Tianjin medical university TMUSPIP** 2023 - 2024
Tianjin Medical University [🌐]
 - Participated in TMUSPIP, Tianjin Medical University's social practice initiative, for three consecutive years as a project leader or core team member; each year successfully secured university-level funding and completed the project with approved final reports; Got over 3 awards in TMUSPIP.